Bruce Cozadd - Jazz Pharmaceuticals Chairman of the Board, CEO
| J7Z Stock | EUR 118.85 2.00 1.71% |
Chairman
Mr. Bruce C. Cozadd is the Chairman of the Board, Chief Executive Officer of Jazz Pharmaceuticals PLC. Mr. Cozadd has served as our Chairman and Chief Executive Officer since the closing of the Azur Merger in January 2012. He cofounded Jazz Pharmaceuticals, Inc. and has served as Chairman and Chief Executive Officer of Jazz Pharmaceuticals, Inc. since April 2009. From 2003 until 2009, he served as Jazz Pharmaceuticals, Inc.s Executive Chairman and as a member of its board of directors. From 1991 until 2001, he held various positions with ALZA Corporationrationration, a pharmaceutical company acquired by Johnson Johnson, most recently as Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporationrationration, he held the roles of Chief Financial Officer and Vice President, Corporationrationrate Planning and Analysis. He serves on the boards of two nonprofit organizations, The Nueva School and SFJAZZ. Mr. Cozadd previously served on the boards of directors of Cerus Corporation from 2001 to January 2018 and Threshold Pharmaceuticals, Inc. from 2005 to August 2017 since 2009.
| Age | 59 |
| Tenure | 15 years |
| Professional Marks | MBA |
| Phone | 353 1 634 7800 |
| Web | https://www.jazzpharma.com |
Bruce Cozadd Latest Insider Activity
Tracking and analyzing the buying and selling activities of Bruce Cozadd against Jazz Pharmaceuticals stock is an integral part of due diligence when investing in Jazz Pharmaceuticals. Bruce Cozadd insider activity provides valuable insight into whether Jazz Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Jazz Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Jazz Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Bruce Cozadd over a month ago Disposition of 1000 shares by Bruce Cozadd of Jazz Pharmaceuticals at 110.84 subject to Rule 16b-3 |
Jazz Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.053 % which means that it generated a profit of $0.053 on every $100 spent on assets. This is way below average. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -0.0056 | |||
| Return On Asset | 0.053 |
Jazz Pharmaceuticals plc Leadership Team
Elected by the shareholders, the Jazz Pharmaceuticals' board of directors comprises two types of representatives: Jazz Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jazz. The board's role is to monitor Jazz Pharmaceuticals' management team and ensure that shareholders' interests are well served. Jazz Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jazz Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert MD, Ex RD | ||
| Finbar Larkin, VP Operations | ||
| George Eliades, Sr Officer | ||
| Daniel Swisher, President COO | ||
| Patricia Carr, VP Officer | ||
| Heidi Manna, VP Officer | ||
| Neena JD, Ex Officer | ||
| Renee Gala, Ex CFO | ||
| Andrea Flynn, VP Relations | ||
| Bruce Cozadd, Chairman of the Board, CEO |
Jazz Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jazz Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0056 | |||
| Return On Asset | 0.053 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 13.72 B | |||
| Shares Outstanding | 62.97 M | |||
| Shares Owned By Insiders | 2.52 % | |||
| Shares Owned By Institutions | 93.17 % | |||
| Price To Earning | 15.29 X | |||
| Price To Book | 3.49 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Jazz Stock
When determining whether Jazz Pharmaceuticals plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Jazz Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Jazz Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Jazz Pharmaceuticals Plc Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.